Arcadia Biosciences, Inc. 8-K

What Happened Arcadia Biosciences, Inc. filed an 8-K reporting that two members of its board resigned effective February 4, 2026. Albert D. Bolles, Ph.D., a director and member of the Compensation Committee, and Deborah Carosella, a director and member of the Compensation Committee and Nominating and Governance Committee, each notified the company of their resignations on February 4, 2026. The company’s report (signed by CEO Thomas J. Schaefer on February 6, 2026) states the resignations were not due to any disagreement with the company or the board and that both have agreed to be available to provide assistance as advisors.

Key Details

• Resignation effective date: February 4, 2026.
• Directors who resigned: Albert D. Bolles, Ph.D.; Deborah Carosella.
• Committee roles: Bolles — Compensation Committee; Carosella — Compensation Committee and Nominating and Governance Committee.
• Company statement: Resignations not due to any disagreement; both agreed to be available as advisors.
• Filing: Form 8-K signed by CEO Thomas J. Schaefer on February 6, 2026.

Why It Matters Board departures can affect governance and committee functioning—here, two members of the Compensation Committee (and one of the Nominating and Governance Committee) left simultaneously, which may prompt the company to appoint replacements or reconstitute committees. The filing explicitly states there was no disagreement with management, which reduces immediate governance risk. Investors should watch for follow-up disclosures about new director appointments or committee changes, as those can influence oversight of executive pay, succession planning, and corporate governance.